BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 33692125)

  • 1. S-nitrosylated TDP-43 triggers aggregation, cell-to-cell spread, and neurotoxicity in hiPSCs and in vivo models of ALS/FTD.
    Pirie E; Oh CK; Zhang X; Han X; Cieplak P; Scott HR; Deal AK; Ghatak S; Martinez FJ; Yeo GW; Yates JR; Nakamura T; Lipton SA
    Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33692125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-Molecule Modulation of TDP-43 Recruitment to Stress Granules Prevents Persistent TDP-43 Accumulation in ALS/FTD.
    Fang MY; Markmiller S; Vu AQ; Javaherian A; Dowdle WE; Jolivet P; Bushway PJ; Castello NA; Baral A; Chan MY; Linsley JW; Linsley D; Mercola M; Finkbeiner S; Lecuyer E; Lewcock JW; Yeo GW
    Neuron; 2019 Sep; 103(5):802-819.e11. PubMed ID: 31272829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia.
    Montalbano M; McAllen S; Cascio FL; Sengupta U; Garcia S; Bhatt N; Ellsworth A; Heidelman EA; Johnson OD; Doskocil S; Kayed R
    Neurobiol Dis; 2020 Dec; 146():105130. PubMed ID: 33065281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct responses of neurons and astrocytes to TDP-43 proteinopathy in amyotrophic lateral sclerosis.
    Smethurst P; Risse E; Tyzack GE; Mitchell JS; Taha DM; Chen YR; Newcombe J; Collinge J; Sidle K; Patani R
    Brain; 2020 Feb; 143(2):430-440. PubMed ID: 32040555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TDP-43 is a ubiquitylation substrate of the SCF
    Rayner SL; Yang S; Farrawell NE; Jagaraj CJ; Cheng F; Davidson JM; Luu L; Redondo AG; Rábano A; Borrego-Hernández D; Atkin JD; Morsch M; Blair IP; Yerbury JJ; Chung R; Lee A
    Neurobiol Dis; 2022 Jun; 167():105673. PubMed ID: 35231559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TDP-43 and Inflammation: Implications for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.
    Bright F; Chan G; van Hummel A; Ittner LM; Ke YD
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain.
    Umoh ME; Dammer EB; Dai J; Duong DM; Lah JJ; Levey AI; Gearing M; Glass JD; Seyfried NT
    EMBO Mol Med; 2018 Jan; 10(1):48-62. PubMed ID: 29191947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of autophagy mitigates TDP-43 pathology and translational repression of neurofilament mRNAs in mouse models of ALS/FTD.
    Kumar S; Phaneuf D; Cordeau P; Boutej H; Kriz J; Julien JP
    Mol Neurodegener; 2021 Jan; 16(1):1. PubMed ID: 33413517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TDP-43 stabilizes G3BP1 mRNA: relevance to amyotrophic lateral sclerosis/frontotemporal dementia.
    Sidibé H; Khalfallah Y; Xiao S; Gómez NB; Fakim H; Tank EMH; Di Tomasso G; Bareke E; Aulas A; McKeever PM; Melamed Z; Destroimaisons L; Deshaies JE; Zinman L; Parker JA; Legault P; Tétreault M; Barmada SJ; Robertson J; Vande Velde C
    Brain; 2021 Dec; 144(11):3461-3476. PubMed ID: 34115105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reappraisal of the anatomical spreading and propagation hypothesis about TDP-43 aggregation in amyotrophic lateral sclerosis and frontotemporal lobar degeneration.
    Riku Y
    Neuropathology; 2020 Oct; 40(5):426-435. PubMed ID: 32157757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase to Phase with TDP-43.
    Sun Y; Chakrabartty A
    Biochemistry; 2017 Feb; 56(6):809-823. PubMed ID: 28112502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody against TDP-43 phosphorylated at serine 375 suggests conformational differences of TDP-43 aggregates among FTLD-TDP subtypes.
    Neumann M; Frick P; Paron F; Kosten J; Buratti E; Mackenzie IR
    Acta Neuropathol; 2020 Nov; 140(5):645-658. PubMed ID: 32778941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling TDP-43 proteinopathy in Drosophila uncovers shared and neuron-specific targets across ALS and FTD relevant circuits.
    Godfrey RK; Alsop E; Bjork RT; Chauhan BS; Ruvalcaba HC; Antone J; Gittings LM; Michael AF; Williams C; Hala'ufia G; Blythe AD; Hall M; Sattler R; Van Keuren-Jensen K; Zarnescu DC
    Acta Neuropathol Commun; 2023 Oct; 11(1):168. PubMed ID: 37864255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD.
    Chou CC; Zhang Y; Umoh ME; Vaughan SW; Lorenzini I; Liu F; Sayegh M; Donlin-Asp PG; Chen YH; Duong DM; Seyfried NT; Powers MA; Kukar T; Hales CM; Gearing M; Cairns NJ; Boylan KB; Dickson DW; Rademakers R; Zhang YJ; Petrucelli L; Sattler R; Zarnescu DC; Glass JD; Rossoll W
    Nat Neurosci; 2018 Feb; 21(2):228-239. PubMed ID: 29311743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TDP-43-mediated neurodegeneration: towards a loss-of-function hypothesis?
    Vanden Broeck L; Callaerts P; Dermaut B
    Trends Mol Med; 2014 Feb; 20(2):66-71. PubMed ID: 24355761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of TDP-43 Proteinopathy Onset and Propagation.
    Chen HJ; Mitchell JC
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging roles of microRNAs in the pathogenesis of frontotemporal dementia-amyotrophic lateral sclerosis (FTD-ALS) spectrum disorders.
    Gascon E; Gao FB
    J Neurogenet; 2014; 28(1-2):30-40. PubMed ID: 24506814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disulfide cross-linked multimers of TDP-43 and spinal motoneuron loss in a TDP-43
    Bargsted L; Medinas DB; Martínez Traub F; Rozas P; Muñoz N; Nassif M; Jerez C; Catenaccio A; Court FA; Hetz C; Matus S
    Sci Rep; 2017 Oct; 7(1):14266. PubMed ID: 29079747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and neuropathological features of ALS/FTD with TIA1 mutations.
    Hirsch-Reinshagen V; Pottier C; Nicholson AM; Baker M; Hsiung GR; Krieger C; Sengdy P; Boylan KB; Dickson DW; Mesulam M; Weintraub S; Bigio E; Zinman L; Keith J; Rogaeva E; Zivkovic SA; Lacomis D; Taylor JP; Rademakers R; Mackenzie IRA
    Acta Neuropathol Commun; 2017 Dec; 5(1):96. PubMed ID: 29216908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear transport dysfunction: a common theme in amyotrophic lateral sclerosis and frontotemporal dementia.
    Jovičić A; Paul JW; Gitler AD
    J Neurochem; 2016 Aug; 138 Suppl 1():134-44. PubMed ID: 27087014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.